Castle Biosciences, Inc. $CSTL Shares Acquired by American Century Companies Inc.

American Century Companies Inc. increased its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 7.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 74,067 shares of the company’s stock after purchasing an additional 4,892 shares during the period. American Century Companies Inc. owned 0.26% of Castle Biosciences worth $1,483,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of CSTL. Allspring Global Investments Holdings LLC lifted its holdings in Castle Biosciences by 2,070.8% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 217,794 shares of the company’s stock worth $4,360,000 after buying an additional 207,761 shares during the last quarter. ProShare Advisors LLC purchased a new stake in Castle Biosciences during the fourth quarter worth approximately $230,000. Deutsche Bank AG boosted its holdings in Castle Biosciences by 12.5% in the fourth quarter. Deutsche Bank AG now owns 67,667 shares of the company’s stock valued at $1,803,000 after purchasing an additional 7,495 shares in the last quarter. D. E. Shaw & Co. Inc. purchased a new position in Castle Biosciences in the fourth quarter valued at approximately $2,414,000. Finally, Man Group plc acquired a new stake in Castle Biosciences during the fourth quarter worth approximately $354,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Castle Biosciences Price Performance

Castle Biosciences stock opened at $24.21 on Wednesday. Castle Biosciences, Inc. has a 12 month low of $14.59 and a 12 month high of $35.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.85 and a quick ratio of 6.69. The business has a 50 day simple moving average of $19.29 and a 200-day simple moving average of $19.51. The stock has a market capitalization of $702.33 million, a PE ratio of -69.17 and a beta of 1.07.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Monday, August 4th. The company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.66. Castle Biosciences had a positive return on equity of 2.37% and a negative net margin of 2.73%.The firm had revenue of $86.18 million for the quarter, compared to analyst estimates of $71.53 million. Castle Biosciences has set its FY 2025 guidance at EPS. Equities analysts predict that Castle Biosciences, Inc. will post 0.44 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on CSTL. Lake Street Capital reduced their price target on shares of Castle Biosciences from $40.00 to $35.00 and set a “buy” rating for the company in a research report on Tuesday, May 6th. Scotiabank reduced their target price on Castle Biosciences from $44.00 to $40.00 and set a “sector outperform” rating for the company in a report on Wednesday, May 21st. Zacks Research raised Castle Biosciences from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Canaccord Genuity Group dropped their price target on Castle Biosciences from $42.00 to $37.00 and set a “buy” rating on the stock in a research note on Tuesday, May 6th. Finally, Wall Street Zen upgraded Castle Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 10th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $37.00.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.